Entering text into the input field will update the search result below

Global Aptamers Market Reaps Benefits Of Higher Use Of Aptamers In Therapeutics Development

Feb. 22, 2016 7:48 AM ETTMR
jessbruce profile picture
jessbruce's Blog
26 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

The growing use of aptamers in drug discovery, pharmaceutical studies, as well as disease treatment will help drive the global aptamers market through the current decade, says Transparency Market Research in a recent study. The report is titled 'Aptamers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.' According to the report, the global aptamers market was valued at US$93.0 million in 2012, and it is expected that the market will reach a valuation of US$4,333.0 million by 2019. This translates to a remarkable CAGR of 73.1% between 2013 and 2019.

Get Report Sample and Customization:
http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1335

However, the report also warns that the growth in the global aptamers market will be restrained to some extent ethical issues associated with aptamers derived from animals. This drawback will be further compounded by strict regulatory mandates designed around aptamers. However, these drawbacks can be overcome by companies in the global aptamers market by modifying aptamers chemistry. For instance, animal-derived aptamers can be replaced by aptamers obtained via the in-vitro process.

For the purpose of this study, the global aptamers market is segmented on the basis of types, applications, and geography. The types of aptamers studied in the report include peptide and nucleic acid aptamers. The segment of nucleic acid aptamers was not only the largest as of 2012, but is also expected to be the fastest growing over the report's forecast period. This is chiefly owing to the widespread use of nucleic acid aptamers in the R&D sector.

Likewise, the applications analyzed in the report are: Diagnostics, therapeutics development, research and development, and others. Of these, the diagnostics segment will report consistent growth over the next four years as the demand for aptamers for biomedical diagnostics, biomarker development, and molecular imaging remains steady. However, in terms of pace of growth, therapeutics development applications will outpace all other application segments over the report's forecast period.

From the geographical standpoint, the aptamers market for the following regions is studied: North America, Asia Pacific, Europe, and Rest of the World. Thanks to several key players in the aptamers market being based in the United States, the North America region was identified as the largest market for aptamers in 2012. This factor also creates an environment that fosters R&D related to aptamers.

The Europe aptamers market was the second largest from the global standpoint. According to the findings of the report, Europe constituted about 35% of the global aptamers market in 2012. Small scale industries play a key role in keeping the Europe aptamers market firmly on the growth track. The Asia Pacific market is currently brimming with opportunities in diagnostics and pharmaceuticals, enabling the region to post the highest CAGR between 2013 and 2019.

TMR's report also conducts a detailed analysis of the competitive scenario in the global aptamers market, which is characterized by intense competition. A high degree of competition has stimulated higher investments the development of novel aptamers. Leading market participants include: Somalogic, Inc., Aptamer Science, Inc. NOXXAN Pharma AG, and Aptagen, Inc.

Full Research Report on Global Aptamers Market with detailed figures and segmentation at: http://www.transparencymarketresearch.com/aptamers-market.html

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You